Literature DB >> 32037127

Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohort.

Linda Levi1, Mor Bar Haim1, Shimon Burshtein1, Inge Winter-Van Rossum2, Stephan Heres3, Michael Davidson4, Geva Shenkman5, René S Kahn6, Mark Weiser7.   

Abstract

Some, but not all, studies have found longer duration of untreated psychosis (DUP) to be associated with poor response to treatment and more severe negative symptoms in schizophrenia. The aim of the current analysis was to investigate these parameters in a large cohort of patients in their first psychotic episode. The OPTiMiSE cohort included 446 patients with DUP up to two years, who were administered amisulpride for 4 weeks (Phase I). Patients who did not meet Andreasen remission criteria were randomized to double-blind continuation of amisulpride or olanzapine for 6 additional weeks in a blinded study (Phase II). Analyses showed that shorter DUP was associated with lower baseline CGI scores (p<0.001, r = 0.184), PANSS total (p = 0.025, r = 0.106) and PANSS negative subscale scores (p = 0.023, r = 0.107). Remitters had a significantly shorter mean DUP compared to non-remitters both in Phase I (24.5 weeks ±24.3 vs. 35 weeks ± 32.2, p = 0.01, t=-2.521) and in Phase II (24.3 weeks ± 26.4 vs. 38.3 weeks ± 31.3, p = 0.031, t=-2.194). Logistic regression analyses showed a significant effect of DUP on treatment response both in phase I (p = 0.008) and phase II (p = 0.041). Linear regression analyses found that DUP significantly affects PANSS Total change at the end of phase I (p = 0.028) but not at the end of phase II (p = 0.236). Based on these findings, it is possible to conclude that shorter DUP is associated with better response to treatment, particularly during the first weeks after treatment initiation. These findings highlight the need for early identification of the first psychotic episode.
Copyright © 2020 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  DUP; First episode; Response; Schizophrenia

Year:  2020        PMID: 32037127     DOI: 10.1016/j.euroneuro.2020.01.007

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  2 in total

1.  Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial.

Authors:  Iris E Sommer; Shiral S Gangadin; Lot D de Witte; Sanne Koops; C van Baal; Sabine Bahn; Hemmo Drexhage; N E M van Haren; Wim Veling; R Bruggeman; Peter Martens; Sybren Wiersma; Selene R T Veerman; Koen P Grootens; Nico van Beveren; Rene S Kahn; Marieke J H Begemann
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

2.  Duration of Untreated Disorder and Cannabis Use: An Observational Study on a Cohort of Young Italian Patients Experiencing Psychotic Experiences and Dissociative Symptoms.

Authors:  Valerio Ricci; Giovanni Martinotti; Franca Ceci; Stefania Chiappini; Francesco Di Carlo; Julius Burkauskas; Ottavia Susini; Debora Luciani; Diego Quattrone; Domenico De Berardis; Mauro Pettorruso; Giuseppe Maina; Massimo Di Giannantonio
Journal:  Int J Environ Res Public Health       Date:  2021-11-30       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.